Sirna, Alnylam, Cenix, Bayer, Fisher, Cellomics, CytRx, Nastech, Isis, Lilly, Qiagen, Xantos, Bio-Rad | GenomeWeb

Sirna Posts Higher Q2 Revenues, Lower Losses

Sirna Therapeutics reported this week a sharp increase in second-quarter revenues, which helped to push down the company's losses.

The company posted revenues of $1.5 million in the quarter, up from $454,000 in the year-ago period, reflecting a surge in fees received from contract manufacturing services.

Sirna's second-quarter net loss arrived at $5.9 million, or $0.14 per share, versus $6.3 million, or $0.18 per share a year earlier.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.